MicroPort CardioFlow Medtech Corp. (HK:2160)
:2160
Want to see HK:2160 full AI Analyst Report?
2160 Stock Chart & Stats
HK$1.25
HK$0.04(6.15%)
At close: 4:00 PM EST
HK$1.25
HK$0.04(6.15%)
Day’s Range― - ―
52-Week RangeHK$1.61 - HK$8.46
Previous CloseN/A
Volume546.00K
Average Volume (3M)8.07M
Market Cap
HK$2.13B
Enterprise ValueHK$450.53M
Total Cash (Recent Filing)HK$1.24B
Total Debt (Recent Filing)HK$232.24M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding1,273,311,400
10 Day Avg. Volume7,535,058
30 Day Avg. Volume8,069,439
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)1.49
Price to Sales (P/S)6.70
P/FCF Ratio-69.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.3
Revenue Forecast (FY)HK$2.18B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent top-line growth (399.4M in 2025, +8.7% YoY) shows durable product demand and expanding market penetration. Over 2–6 months this supports scale benefits, steadier distributor/hospital relationships and a clearer path to operational leverage if cost structure is managed.
Solid Gross MarginA roughly 55% gross margin indicates strong product-level economics common in medtech, enabling pricing power and coverage of fixed costs. This margin profile is a durable advantage that can underpin future operating profitability as sales scale and incremental revenues drop to the bottom line.
Lower Cash Burn Vs Prior YearsA materially reduced cash burn versus 2021–2024 reflects improving operational efficiency and nearer-term progress toward self-funding. Over the coming months this shrinks refinancing urgency and extends runway, giving management more time to convert revenue growth into profits.
Bears Say
Elevated LeverageA sharp rise in debt to ~1.62B and debt/equity near 6.3x materially increases refinancing, interest and covenant risk while the company remains loss-making. This structurally limits financial flexibility, compresses options for R&D or commercialization investment, and heightens vulnerability to credit market shifts.
Negative Free Cash FlowPersistent negative FCF (≈-38.3M in 2025) means ongoing reliance on external funding to sustain operations and growth. With elevated leverage this creates liquidity pressure, raises the probability of dilutive capital raises or higher-cost borrowing, and constrains multi-quarter strategic initiatives.
Worsening Net LossesDeepening losses (net margin ≈-33%) signal that revenue growth has not yet produced sustainable profitability. Over months this prolongs dependence on external capital, impedes return on equity, and raises execution risk around translating scale and margins into durable earnings.
MicroPort CardioFlow Medtech Corp. News
2160 FAQ
What was MicroPort CardioFlow Medtech Corp.’s price range in the past 12 months?
MicroPort CardioFlow Medtech Corp. lowest stock price was HK$1.61 and its highest was HK$8.46 in the past 12 months.
What is MicroPort CardioFlow Medtech Corp.’s market cap?
MicroPort CardioFlow Medtech Corp.’s market cap is HK$2.13B.
When is MicroPort CardioFlow Medtech Corp.’s upcoming earnings report date?
MicroPort CardioFlow Medtech Corp.’s upcoming earnings report date is Sep 02, 2026 which is in 89 days.
How were MicroPort CardioFlow Medtech Corp.’s earnings last quarter?
Currently, no data Available
Is MicroPort CardioFlow Medtech Corp. overvalued?
According to Wall Street analysts MicroPort CardioFlow Medtech Corp.’s price is currently Overvalued.
Does MicroPort CardioFlow Medtech Corp. pay dividends?
MicroPort CardioFlow Medtech Corp. does not currently pay dividends.
What is MicroPort CardioFlow Medtech Corp.’s EPS estimate?
MicroPort CardioFlow Medtech Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MicroPort CardioFlow Medtech Corp. have?
MicroPort CardioFlow Medtech Corp. has 1,273,311,400 shares outstanding.
What happened to MicroPort CardioFlow Medtech Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MicroPort CardioFlow Medtech Corp.?
Currently, no hedge funds are holding shares in HK:2160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MicroPort CardioFlow Medtech Corp. Stock Smart Score
Company Description
MicroPort CardioFlow Medtech Corp.
MicroPort CardioFlow Medtech Corporation, a medical device company, researches, develops, and commercializes transcatheter and surgical solutions for structural heart diseases in the People's Republic of China. It offers Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set to target aortic, mitral, tricuspid, and surgical valves, as well as procedural accessories. The company was founded in 2010 and is headquartered in Shanghai, China.
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
AK Medical Holdings Ltd.
―
Venus Medtech (Hangzhou), Inc. Class H
―
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
―
Options Prices
Currently, No data available
---